From: Longitudinal changes of blood parameters and weight in inoperable stage III NSCLC patients treated with concurrent chemoradiotherapy followed by maintenance treatment with durvalumab
Before cCRT
Before Durvalumab
3-month follow-up
6-month follow-up
9-month follow-up
12-month follow-up
Patient values
22
19
18
CRP ≤5
20 (91%)
21 (95%)
19 (86%)
17 (89%)
18 (95%)
18 (100%)
CRP > 5
2 (9%)
1 (5%)
3 (14%)
2 (11%)
0